Problematic Dichotomization of Risk for Intensive Care Unit (ICU)-Acquired Invasive Candidiasis: Results Using a Risk-Predictive Model to Categorize 3 Levels of Risk From a Multicenter Prospective Cohort of Australian ICU Patients

Clin Infect Dis. 2016 Dec 1;63(11):1463-1469. doi: 10.1093/cid/ciw610. Epub 2016 Sep 6.

Abstract

Background: Delayed antifungal therapy for invasive candidiasis (IC) contributes to poor outcomes. Predictive risk models may allow targeted antifungal prophylaxis to those at greatest risk.

Methods: A prospective cohort study of 6685 consecutive nonneutropenic patients admitted to 7 Australian intensive care units (ICUs) for ≥72 hours was performed. Clinical risk factors for IC occurring prior to and following ICU admission, colonization with Candida species on surveillance cultures from 3 sites assessed twice weekly, and the occurrence of IC ≥72 hours following ICU admission or ≤72 hours following ICU discharge were measured. From these parameters, a risk-predictive model for the development of ICU-acquired IC was then derived.

Results: Ninety-six patients (1.43%) developed ICU-acquired IC. A simple summation risk-predictive model using the 10 independently significant variables associated with IC demonstrated overall moderate accuracy (area under the receiver operating characteristic curve = 0.82). No single threshold score could categorize patients into clinically useful high- and low-risk groups. However, using 2 threshold scores, 3 patient cohorts could be identified: those at high risk (score ≥6, 4.8% of total cohort, positive predictive value [PPV] 11.7%), those at low risk (score ≤2, 43.1% of total cohort, PPV 0.24%), and those at intermediate risk (score 3-5, 52.1% of total cohort, PPV 1.46%).

Conclusions: Dichotomization of ICU patients into high- and low-risk groups for IC risk is problematic. Categorizing patients into high-, intermediate-, and low-risk groups may more efficiently target early antifungal strategies and utilization of newer diagnostic tests.

Keywords: candidemia; critical care; invasive candidiasis; prophylaxis; risk prediction.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Antifungal Agents / therapeutic use
  • Australia / epidemiology
  • Candida / isolation & purification
  • Candidiasis / epidemiology
  • Candidiasis / microbiology
  • Candidiasis / prevention & control
  • Candidiasis, Invasive / drug therapy
  • Candidiasis, Invasive / epidemiology*
  • Candidiasis, Invasive / microbiology
  • Candidiasis, Invasive / prevention & control
  • Cohort Studies
  • Critical Illness
  • Cross Infection / epidemiology*
  • Cross Infection / microbiology
  • Cross Infection / prevention & control
  • Female
  • Humans
  • Intensive Care Units*
  • Male
  • Middle Aged
  • Models, Theoretical
  • Predictive Value of Tests
  • Prospective Studies
  • ROC Curve
  • Risk Assessment
  • Risk Factors

Substances

  • Antifungal Agents

Supplementary concepts

  • Systemic candidiasis